| 1 |
28611279 | Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment. | 2017 Jun 27 |
3 |
| 2 |
23227342 | Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an immunocytochemical study. | 2012 |
1 |
| 3 |
21424111 | Activated protein C inhibits bisphosphonate-induced endothelial cell death via the endothelial protein C receptor and nuclear factor-κB pathways. | 2011 Jun |
2 |
| 4 |
21714093 | Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption. | 2011 Jul 4 |
3 |
| 5 |
19070762 | Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. | 2009 Jan |
5 |
| 6 |
15921672 | Autoactivation profiles of calcium-dependent matrix metalloproteinase-2 and -9 in inflammatory synovial fluid: effect of pyrophosphate and bisphosphonates. | 2005 Aug |
1 |
| 7 |
15046690 | National Cancer Institute intramural approach to advanced prostate cancer. | 2002 Dec |
1 |
| 8 |
11211310 | Effects of bisphosphonate on the release of MMP-2 from cultured human osteoblasts. | 2000 Oct |
6 |
| 9 |
9626812 | Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. | 1998 May |
1 |
| 10 |
9679953 | Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate. | 1998 Jul 15 |
1 |